U.S., June 12 -- ClinicalTrials.gov registry received information related to the study (NCT07015801) titled 'CMV-specific Donor-derived T Lymphocytes for the Treatment of Recalcitrant CMV Infection in a Patient With Primary Immunodeficiency' on May 22.
Brief Summary: Treatment of CMV in a patient with profound combined immunodeficiency, who has viremia and pneumonia, using CMV-specific donor-derived T lymphocytes (CMV-VST).
Study Start Date: April 15
Study Type: INTERVENTIONAL
Condition:
Cytomegalovirus Viremia
Cytomegalovirus Pneumonia
T-Lymphocyte Immunodeficiency
Intervention:
BIOLOGICAL: CMV-VST
30-40 x 10^3 viable CD3+ cells/kg
Recruitment Status: ACTIVE_NOT_RECRUITING
Sponsor: University of Calgary
Published by HT Digital C...